Personalized medicine Interpace Biosciences operates across the therapeutic value chain with a focus on personalized medicine, indicating opportunities to cross-sell diagnostic tests, prognostic tools, and pharmacogenomics services to pharma, biotech, and healthcare providers pursuing tailored treatments.

Diagnostics expansion Active growth in Interpace Diagnostics with newly launched pleural biopsy system and thyroid cancer test platform validation suggests upsell potential for complementary molecular tests, pathology services, and bioinformatics support to hospitals and clinics expanding cancer diagnostic programs.

Pharmacogenomics focus Pharmacogenomics testing and biorepository services position Interpace as a partner for pharma and biotech in drug development and clinical trials, offering collaboration opportunities to integrate genomic data into safier, faster drug development pipelines.

Reimbursement momentum Recent progress on PancraGEN reimbursement signals a favorable market environment for market access support services, paving the way for sales of reimbursement strategy consulting, coding, and value demonstration packages to healthcare providers and payers.

Strategic partnerships Past collaborations with Twist Bioscience and Genecast Biotechnology indicate a receptivity to technology partnerships, suggesting expansion paths through co-development, data integration, and translational study programs with biotech and biopharma customers.